vs
HomeTrust Bancshares, Inc.（HTB）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
HomeTrust Bancshares, Inc.的季度营收约是Xtant Medical Holdings, Inc.的1.7倍（$53.6M vs $32.4M），HomeTrust Bancshares, Inc.同比增速更快（3.7% vs 2.7%），HomeTrust Bancshares, Inc.自由现金流更多（$45.3M vs $5.0M），过去两年Xtant Medical Holdings, Inc.的营收复合增速更高（7.7% vs 3.5%）
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
HTB vs XTNT — 直观对比
营收规模更大
HTB
是对方的1.7倍
$32.4M
营收增速更快
HTB
高出1.0%
2.7%
自由现金流更多
HTB
多$40.3M
$5.0M
两年增速更快
XTNT
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $32.4M |
| 净利润 | — | $57.0K |
| 毛利率 | — | 54.9% |
| 营业利润率 | 37.0% | -2.9% |
| 净利率 | — | 0.2% |
| 营收同比 | 3.7% | 2.7% |
| 净利润同比 | — | 101.8% |
| 每股收益（稀释后） | $0.93 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBXTNT
| Q4 25 | $53.6M | $32.4M | ||
| Q3 25 | $54.1M | $33.3M | ||
| Q2 25 | $54.4M | $35.4M | ||
| Q1 25 | $50.9M | $32.9M | ||
| Q4 24 | $51.7M | $31.5M | ||
| Q3 24 | $50.6M | $27.9M | ||
| Q2 24 | $50.6M | $29.9M | ||
| Q1 24 | $50.0M | $27.9M |
净利润HTBXTNT
| Q4 25 | — | $57.0K | ||
| Q3 25 | $16.5M | $1.3M | ||
| Q2 25 | $17.2M | $3.5M | ||
| Q1 25 | $14.5M | $58.0K | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $13.1M | $-5.0M | ||
| Q2 24 | $12.4M | $-3.9M | ||
| Q1 24 | $15.1M | $-4.4M |
毛利率HTBXTNT
| Q4 25 | — | 54.9% | ||
| Q3 25 | — | 66.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | — | 62.1% | ||
| Q1 24 | — | 62.1% |
营业利润率HTBXTNT
| Q4 25 | 37.0% | -2.9% | ||
| Q3 25 | 38.5% | 7.6% | ||
| Q2 25 | 40.1% | 13.1% | ||
| Q1 25 | 36.2% | 3.2% | ||
| Q4 24 | 35.4% | -6.0% | ||
| Q3 24 | 33.2% | -13.5% | ||
| Q2 24 | 31.3% | -9.8% | ||
| Q1 24 | 38.0% | -12.4% |
净利率HTBXTNT
| Q4 25 | — | 0.2% | ||
| Q3 25 | 30.5% | 3.9% | ||
| Q2 25 | 31.6% | 10.0% | ||
| Q1 25 | 28.5% | 0.2% | ||
| Q4 24 | — | -10.0% | ||
| Q3 24 | 25.9% | -18.0% | ||
| Q2 24 | 24.6% | -12.9% | ||
| Q1 24 | 30.1% | -15.8% |
每股收益（稀释后）HTBXTNT
| Q4 25 | $0.93 | $0.00 | ||
| Q3 25 | $0.95 | $0.01 | ||
| Q2 25 | $1.00 | $0.02 | ||
| Q1 25 | $0.84 | $0.00 | ||
| Q4 24 | $0.83 | $-0.02 | ||
| Q3 24 | $0.76 | $-0.04 | ||
| Q2 24 | $0.73 | $-0.03 | ||
| Q1 24 | $0.88 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.7M | $17.1M |
| 总债务越低越好 | — | $11.0M |
| 股东权益账面价值 | $600.7M | $51.0M |
| 总资产 | $4.5B | $94.1M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资HTBXTNT
| Q4 25 | $324.7M | $17.1M | ||
| Q3 25 | $315.8M | $10.4M | ||
| Q2 25 | $297.2M | $6.9M | ||
| Q1 25 | $299.8M | $5.0M | ||
| Q4 24 | $279.2M | $6.2M | ||
| Q3 24 | $293.5M | $6.6M | ||
| Q2 24 | $294.2M | $5.4M | ||
| Q1 24 | $380.5M | $4.5M |
总债务HTBXTNT
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益HTBXTNT
| Q4 25 | $600.7M | $51.0M | ||
| Q3 25 | $595.8M | $50.4M | ||
| Q2 25 | $579.3M | $48.5M | ||
| Q1 25 | $565.4M | $43.9M | ||
| Q4 24 | $551.8M | $43.0M | ||
| Q3 24 | $540.0M | $45.7M | ||
| Q2 24 | $523.6M | $45.0M | ||
| Q1 24 | $513.2M | $47.7M |
总资产HTBXTNT
| Q4 25 | $4.5B | $94.1M | ||
| Q3 25 | $4.6B | $106.3M | ||
| Q2 25 | $4.6B | $103.5M | ||
| Q1 25 | $4.6B | $95.8M | ||
| Q4 24 | $4.6B | $93.8M | ||
| Q3 24 | $4.6B | $98.9M | ||
| Q2 24 | $4.7B | $95.6M | ||
| Q1 24 | $4.7B | $93.9M |
负债/权益比HTBXTNT
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $45.3M | $5.0M |
| 自由现金流率自由现金流/营收 | 84.5% | 15.4% |
| 资本支出强度资本支出/营收 | 7.8% | 1.2% |
| 现金转化率经营现金流/净利润 | — | 94.39× |
| 过去12个月自由现金流最近4个季度 | $93.8M | $10.2M |
8季度趋势，按日历期对齐
经营现金流HTBXTNT
| Q4 25 | $49.5M | $5.4M | ||
| Q3 25 | $-11.3M | $4.6M | ||
| Q2 25 | $-8.8M | $1.3M | ||
| Q1 25 | $71.7M | $1.3M | ||
| Q4 24 | $45.4M | $665.0K | ||
| Q3 24 | $43.8M | $-1.7M | ||
| Q2 24 | $5.9M | $-5.1M | ||
| Q1 24 | $-9.0M | $-5.8M |
自由现金流HTBXTNT
| Q4 25 | $45.3M | $5.0M | ||
| Q3 25 | $-12.0M | $4.2M | ||
| Q2 25 | $-10.2M | $910.0K | ||
| Q1 25 | $70.7M | $87.0K | ||
| Q4 24 | $42.4M | $-7.0K | ||
| Q3 24 | $43.1M | $-3.8M | ||
| Q2 24 | $5.7M | $-5.7M | ||
| Q1 24 | $-9.6M | $-6.5M |
自由现金流率HTBXTNT
| Q4 25 | 84.5% | 15.4% | ||
| Q3 25 | -22.2% | 12.6% | ||
| Q2 25 | -18.7% | 2.6% | ||
| Q1 25 | 138.7% | 0.3% | ||
| Q4 24 | 82.0% | -0.0% | ||
| Q3 24 | 85.1% | -13.7% | ||
| Q2 24 | 11.2% | -18.9% | ||
| Q1 24 | -19.2% | -23.4% |
资本支出强度HTBXTNT
| Q4 25 | 7.8% | 1.2% | ||
| Q3 25 | 1.4% | 1.3% | ||
| Q2 25 | 2.5% | 1.0% | ||
| Q1 25 | 2.0% | 3.6% | ||
| Q4 24 | 5.9% | 2.1% | ||
| Q3 24 | 1.3% | 7.5% | ||
| Q2 24 | 0.5% | 1.9% | ||
| Q1 24 | 1.1% | 2.8% |
现金转化率HTBXTNT
| Q4 25 | — | 94.39× | ||
| Q3 25 | -0.68× | 3.53× | ||
| Q2 25 | -0.51× | 0.36× | ||
| Q1 25 | 4.93× | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.34× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | -0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTB
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
